How does LIPUM's PB Ratio compare to its peers?

LIPUM is good value based on its Price-To-Book Ratio (7.6x) compared to the peer average (58.8x).

How does LIPUM's PB Ratio compare vs other companies in the SE Biotechs Industry?

LIPUM is expensive based on its Price-To-Book Ratio (7.6x) compared to the Swedish Biotechs industry average (2.4x).

What is LIPUM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate LIPUM's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of LIPUM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate LIPUM's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Lipum (OM:LIPUM) - Stock Price, News & Analysis

LIPUM Stock Overview

A biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. More details

LIPUM fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (SEK53K)

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 22.2% per year for the next 3 years

+ 2 more risks

Lipum AB (publ) Competitors

Kancera

OM:KAN

SEK 130.9m

Active Biotech

OM:ACTI

SEK 344.4m

Abliva

OM:ABLI

SEK 213.4m

Isofol Medical

OM:ISOFOL

SEK 536.2m

Price History & Performance

Summary of all time highs, changes and price drops for Lipum
Historical stock prices
Current Share Price	SEK 17.10
52 Week High	SEK 18.40
52 Week Low	SEK 5.50
Beta	0.15
11 Month Change	18.75%
3 Month Change	37.90%
1 Year Change	92.13%
33 Year Change	-14.50%
5 Year Change	n/a
Change since IPO	-24.72%

Recent updates

Shareholder Returns

	LIPUM	SE Biotechs	SE Market
7D	18.8%	-5.8%	-2.1%
1Y	92.1%	14.3%	10.8%

Return vs Industry: LIPUM exceeded the Swedish Biotechs industry which returned 14.3% over the past year.

Return vs Market: LIPUM exceeded the Swedish Market which returned 10.8% over the past year.

Price Volatility

Is LIPUM's price volatile compared to industry and market?
LIPUM volatility
LIPUM Average Weekly Movement	8.0%
Biotechs Industry Average Movement	9.3%
Market Average Movement	5.6%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: LIPUM has not had significant price volatility in the past 3 months compared to the Swedish market.

Volatility Over Time: LIPUM's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2010	5	Ola Sandborgh	www.lipum.se

Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular.

Lipum AB (publ) Fundamentals Summary

How do Lipum's earnings and revenue compare to its market cap?
LIPUM fundamental statistics
Market cap	SEK 358.49m
Earnings (TTM)	-SEK 39.24m
Revenue (TTM)	SEK 53.00k

6,844x

P/S Ratio

-9.2x

P/E Ratio

Is LIPUM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LIPUM income statement (TTM)
Revenue	SEK 53.00k
Cost of Revenue	SEK 0
Gross Profit	SEK 53.00k
Other Expenses	SEK 39.29m
Earnings	-SEK 39.24m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 26, 2025

Earnings per share (EPS)	-1.85
Gross Margin	100.00%
Net Profit Margin	-74,037.74%
Debt/Equity Ratio	24.7%

How did LIPUM perform over the long term?

See historical performance and comparison

LIPUM Stock Overview

Risk Analysis

Lipum AB (publ) Competitors

OM:KAN

SEK 130.9m

OM:ACTI

SEK 344.4m

OM:ABLI

SEK 213.4m

OM:ISOFOL

SEK 536.2m

Price History & Performance

Recent News & Updates

Lipum AB (publ) to Report Q3, 2024 Results on Oct 25, 2024

Lipum AB (publ) to Report Fiscal Year 2024 Results on Feb 26, 2025

New minor risk - Share price stability

Lipum AB (Publ) Welcomes Peter Hovstadius as Chief Medical Officer

New major risk - Financial position

High number of new directors

Recent updates

Lipum AB (publ) to Report Q3, 2024 Results on Oct 25, 2024

Lipum AB (publ) to Report Fiscal Year 2024 Results on Feb 26, 2025

New minor risk - Share price stability

Lipum AB (Publ) Welcomes Peter Hovstadius as Chief Medical Officer

New major risk - Financial position

High number of new directors

Lipum AB (publ) Completes Multiple Dose Part of the Phase I Clinical Study

Lipum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 79.714945 million.

Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer

Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer

Forecast to breakeven in 2025

Lipum AB (publ) has filed a Follow-on Equity Offering.

Lipum AB (publ) has filed a Follow-on Equity Offering.

Lipum AB (publ) Reports Positive Interim Results from Clinical Phase 1 Study Showing that SOL-116 Reduces Plasma BSSL Levels in Healthy Subjects

Lipum AB (Publ) Receives Funding from Vinnova for an Eurostars Application

Lipum AB (publ) Announces Nomination Committee Appointments

Lipum AB (Publ) Appoints Ola Sandborgh as Chief Executive Officer, Effective from December 1, 2023

New major risk - Revenue and earnings growth

Lipum AB (Publ) Appoints Karin Franck-Larsson as CMO

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Lipum Elects Carl-Johan Spak as New Board Member

Chief Executive Officer recently bought kr161k worth of stock

Lipum AB (publ) Announces the Nomination Committee for the 2023 Annual General Meeting

Chief Executive Officer recently bought kr157k worth of stock

Lipum AB (Publ) Has Initiated A Phase 1 Clinical Study with Its Drug Candidate Sol-116

Lipum AB (publ) announced that it has received SEK 38.999963 million in funding from Flerie Invest AB

Lipum AB (publ) Gets Approval to Start Phase 1 Clinical Trial with Drug Candidate Sol-116

Lipum AB (publ) Appoints Helena Bergström as Chief Medical Officer

Lipum Reports Completion of GLP Toxicology- and Safety Program on the Candidate Drug (SOL-116)

Chief Executive Officer recently bought kr195k worth of stock

Lipum AB (Publ) Reports Gmp Production of Sol-116 Successful

Lipum Recruits Fredrik Seijsing as Scientist

Lipum AB (publ) Initiates GMP-Production for Clinical Trials

Lipum Is At the Final Step Before Clinical Phase

Shareholder Returns

Price Volatility

About the Company

Lipum AB (publ) Fundamentals Summary

6,844x

-9.2x

Earnings & Revenue